Novartis

By Heather Mack March 1, 2017
Digital approaches to healthcare may have the potential to significantly expand coverage and improve the quality and efficiency of patient care, but implementing these new technologies come with challenges of their own, including fragmented data streams, limited resources and ineffective collaboration across multiple sectors. What’s more, access to most basic requirement of digital health...
By Naomi Fried February 10, 2017
About the author: Naomi Fried, PhD (@NaomiFried), is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation infrastructure consulting to healthcare stakeholders including pharma companies and providers. Her previous positions include the first Chief Innovation Officer at Boston Children’s Hospital, Biogen’s VP of Innovation and External Partnerships, and VP...
By Heather Mack February 8, 2017
Digital respiratory health management company Propeller Health is collaborating with Novartis to develop a custom add-on sensor for the Swiss pharmaceutical company’s Breezhaler inhaler, which is used for Novartis’s portfolio of COPD treatments. The partnership will be focused in Europe. The add-on sensor will be developed to work with the capsule-based dry powder inhaler by passively recording...
By Heather Mack November 21, 2016
When will Novartis and Google begin testing the autofocus contact lens they have been developing? Well, there’s still no clear date in sight. The pharmaceutical company announced late last week they had done away with a 2016 goal of testing a smart contact lens for people with nearsightedness, telling Reuters, “It is too early to say when exactly human clinical trials for these lenses will begin...
By Jonah Comstock September 19, 2016
Can the success of digital health coaching apps like Twine Health and WellDoc be ported over to the clinical trial space? According to Joris Van Dam, a strategic projects leader in pharmaceutical development at Novartis, it can and it should. Van Dam spoke at the Mobile in Clinical Trials event today, put on by The Conference Forum.  "The use [of coaching in clinical trials] is a natural fit," he...
By Jonah Comstock June 20, 2016
Exco InTouch has launched a new app that creates a disease-specific social network for people with chronic urticaria, or hives. The app, called Target My Hives, was developed with funding and support from Novartis. The app, available on Android and Apple devices, was just formally announced by the companies, but it currently has 2,000 patients registered from 61 countries. It launched in May....
By Jonah Comstock June 1, 2016
Medella Health, the company whose founding team includes a Thiel Fellow and is racing Google and Novartis to develop a glucose-sensing contact lens, has raised $1.4 million in funding. Backers include 1517 Fund, Fifty Years Fund, Garage Capital, BDC Capital and others.  Not too much is known yet about Medella's lens. The company says it will integrate a small sensor, a chip, and a micro-antenna...
By MHN Staff April 14, 2016
As we do every quarter, MobiHealthNews has rounded up our Q1 2016 coverage into a handful of longform stories. This section is on pharma. Skip ahead using these links to read Q1 digital health news roundups about providers, payers, M&A and funding. Novartis Novartis announced a partnership with Qualcomm Life, a subsidiary of Qualcomm, to develop a connected version of its inhaler, Breezhaler...
By Aditi Pai February 16, 2016
Microsoft has announced a partnership Novartis that began a few years ago to create a system, called Assess MS, that better evaluates how patients perform on multiple sclerosis (MS) tests. The current MS tests require patients to perform movements, like touching their nose or sitting with their arms outstretched. Providers watch the patients and rate their movements on a scale, but ratings that...
By Jonah Comstock February 9, 2016
Novartis has signed deals with two major health plans, Cigna and Aetna, to reimburse for its new heart failure drug Entresto, Reuters reported. The deals are among the first publicly announced examples of outcomes-based drug pricing. While Novartis discussed using digital health devices as part of its planned Entresto rollout last year, reports about the new payer deals have not mentioned the...